Background: A connection between premature adrenarche (PA) and polycystic ovary syndrome (PCOS) has been proposed. We investigated whether anti-müllerian hormone (AMH) production is increased in prepubertal girls with PA, as it is in women with PCOS and in their prepubertal daughters. Methods: Fifty-two prepubertal girls with PA and 48 prepubertal age-matched controls were studied. Serum AMH concentrations were determined by a specific ELISA assay and correlated with baseline steroid hormone, GnRH-stimulated LH and FSH, and glucose and insulin concentrations during an oral glucose tolerance test (OGTT). Results: Girls with PA had lower serum AMH concentrations than their controls (2.65 vs. 3.43 ng/ml, p = 0.035). This difference between the study groups vanished when adjusted for BMI SDS score (SDS) or body fat percentage. In the entire cohort, serum AMH concentration was negatively correlated with BMI SDS (r = –0.23, p = 0.019) and androstenedione (r = –0.22, p = 0.03), but not with age, GnRH-stimulated LH or FSH, baseline or OGTT insulin concentrations. Within the control group only, there was an inverse relationship of serum AMH with DHEAS (r = –0.32, p = 0.028) concentrations. Conclusions: Unlike prepubertal daughters of PCOS women, PA girls do not have abnormalities in serum AMH concentrations at prepubertal age.

1.
Ibáñez L, Dimartino-Nardi J, Potau N, Saenger P: Premature adrenarche – normal variant or forerunner of adult disease? Endocr Rev 2000;21:671–696.
2.
Josso N, Picard JY, Rey R, di Clemente N: Testicular anti-müllerian hormone: history, genetics, regulation and clinical applications. Pediatr Endocrinol Rev 2006;3:347–358.
3.
Voutilainen R, Miller WL: Human müllerian inhibitory factor messenger ribonucleic acid is hormonally regulated in the fetal testis and in adult granulosa cells. Mol Endocrinol 1987;1:604–608.
4.
Visser JA, de Jong FH, Laven JS, Themmen AP: Anti-müllerian hormone: a new marker for ovarian function. Reproduction 2006;131:1–9.
5.
Pigny P, Jonard S, Robert Y, Dewailly D: Serum anti-müllerian hormone as a surrogate for antral follicle count for definition of the polycystic ovary syndrome. J Clin Endocrinol Metab 2006;91:941–945.
6.
Seifer DB, MacLaughlin DT, Christian BP, Feng B, Shelden RM: Early follicular serum müllerian-inhibiting substance levels are associated with ovarian response during assisted reproductive technology cycles. Fertil Steril 2002;77:468–471.
7.
De Vet A, Laven JS, de Jong FH, Themmen AP, Fauser BC: Anti-müllerian hormone serum levels: a putative marker for ovarian aging. Fertil Steril 2002;77:357–362.
8.
Bath LE, Wallace WH, Shaw MP, Fitzpatrick C, Anderson RA: Depletion of ovarian reserve in young women after treatment for cancer in childhood: detection by anti-müllerian hormone, inhibin B and ovarian ultrasound. Hum Reprod 2003;18:2368–2374.
9.
Laven JS, Mulders AG, Visser JA, Themmen AP, De Jong FH, Fauser BC: Anti-müllerian hormone serum concentrations in normoovulatory and anovulatory women of reproductive age. J Clin Endocrinol Metab 2004;89:318–323.
10.
Pigny P, Merlen E, Robert Y, Cortet-Rudelli C, Decanter C, Jonard S, Dewailly D: Elevated serum level of anti-müllerian hormone in patients with polycystic ovary syndrome: relationship to the ovarian follicle excess and to the follicular arrest. J Clin Endocrinol Metab 2003;88:5957–5962.
11.
Siow Y, Kives S, Hertweck P, Perlman S, Fallat ME: Serum müllerian-inhibiting substance levels in adolescent girls with normal menstrual cycles or with polycystic ovary syndrome. Fertil Steril 2005;84:938–944.
12.
Crisosto N, Codner E, Maliqueo M, Echiburu B, Sanchez F, Cassorla F, Sir-Petermann T: Anti-müllerian hormone levels in peripubertal daughters of women with polycystic ovary syndrome. J Clin Endocrinol Metab 2007;92:2739–2743.
13.
Sir-Petermann T, Codner E, Maliqueo M, Echiburu B, Hitschfeld C, Crisosto N, Perez-Bravo F, Recabarren SE, Cassorla F: Increased anti-müllerian hormone serum concentrations in prepubertal daughters of women with polycystic ovary syndrome. J Clin Endocrinol Metab 2006;91:3105–3109.
14.
Utriainen P, Voutilainen R, Jääskeläinen J: Continuum of phenotypes and sympathoadrenal function in premature adrenarche. Eur J Endocrinol 2009;160:657–665.
15.
Utriainen P, Voutilainen R, Jääskeläinen J: Girls with premature adrenarche have accelerated early childhood growth. J Pediatr 2009;154:882–887.
16.
Utriainen P, Jääskeläinen J, Romppanen J, Voutilainen R: Childhood metabolic syndrome and its components in premature adrenarche. J Clin Endocrinol Metab 2007;92:4282–4285.
17.
Ibáñez L, Potau N, Virdis R, Zampolli M, Terzi C, Gussinye M, Carrascosa A, Vicens-Calvet E: Postpubertal outcome in girls diagnosed of premature pubarche during childhood: increased frequency of functional ovarian hyperandrogenism. J Clin Endocrinol Metab 1993;76:1599–1603.
18.
Maliqueo M, Sir-Petermann T, Perez V, Echiburu B, de Guevara AL, Galvez C, Crisosto N, Azziz R: Adrenal function during childhood and puberty in daughters of women with polycystic ovary syndrome. J Clin Endocrinol Metab 2009;94:3282–3288.
19.
Cook CL, Siow Y, Brenner AG, Fallat ME: Relationship between serum müllerian-inhibiting substance and other reproductive hormones in untreated women with polycystic ovary syndrome and normal women. Fertil Steril 2002;77:141–146.
20.
Pellatt L, Hanna L, Brincat M, Galea R, Brain H, Whitehead S, Mason H: Granulosa cell production of anti-müllerian hormone is increased in polycystic ovaries. J Clin Endocrinol Metab 2007;92:240–245.
21.
Freeman EW, Gracia CR, Sammel MD, Lin H, Lim LC, Strauss JF 3rd: Association of anti-müllerian hormone levels with obesity in late reproductive-age women. Fertil Steril 2007;87:101–106.
22.
Steiner AZ, Stanczyk FZ, Patel S, Edelman A: Anti-müllerian hormone and obesity: insights in oral contraceptive users. Contraception 2010;81:245–248.
23.
Piltonen T, Morin-Papunen L, Koivunen R, Perheentupa A, Ruokonen A, Tapanainen JS: Serum anti-müllerian hormone levels remain high until late reproductive age and decrease during metformin therapy in women with polycystic ovary syndrome. Hum Reprod 2005;20:1820–1826.
24.
Park HT, Cho GJ, Ahn KH, Shin JH, Kim YT, Hur JY, Kim SH, Lee KW, Kim T: Association of insulin resistance with anti-müllerian hormone levels in women without polycystic ovary syndrome. Clin Endocrinol (Oxf) 2010;72:26–31.
25.
Seifer DB, Maclaughlin DT: Müllerian-inhibiting substance is an ovarian growth factor of emerging clinical significance. Fertil Steril 2007;88:539–546.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.